{"product_id":"mallinckrodt-pestle-analysis","title":"Mallinckrodt PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political scrutiny, regulatory pressures, economic headwinds, technological shifts, and social trends are reshaping Mallinckrodt’s prospects in our concise PESTLE snapshot; perfect for investors and strategists seeking clarity. Buy the full analysis to access actionable, ready-to-use intelligence now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing scrutiny and reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernments increasingly interrogate specialty drug prices—under the US Inflation Reduction Act Medicare can negotiate prices for high-spend drugs starting in 2026—pressuring coverage and margins for rare-disease therapies. Health technology assessments (eg NICE thresholds ~20,000–30,000 pounds\/QALY) and value-for-money frameworks drive negotiated discounts. With specialty drugs accounting for roughly half of US drug spending, shifts in public payer policies can speed or stall uptake, so Mallinckrodt must align evidence packages to secure favorable reimbursement decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory agency priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFDA\/EMA emphasis on rare diseases can speed reviews via orphan and priority review pathways—priority review shortens FDA review to six months—while FDA has granted over 7,000 orphan designations since 1983, increasing post-market evidence obligations and confirmatory trial commitments. Shifts in guidance on endpoints or trial design can force pipeline redesigns; continuous regulatory engagement is critical for Mallinckrodt to preserve predictability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment procurement and hospital funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCritical care products depend heavily on public hospital budgets and tendering, with OECD data showing government and compulsory schemes financed about 73% of health spending in 2022, making political cycles crucial for neonatal and ICU therapy funding. Centralized procurement programs can compress prices while offering volume stability for suppliers. Participation in strategic stockpiles, expanded after COVID-19, can partially buffer demand volatility for Mallinckrodt. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade policy and supply chain geopolitics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTariffs, export controls and geopolitical tensions constrain access to APIs and specialized inputs, with China and India supplying over 60% of global APIs; unpredictable controls on biologics shipments raise customs friction for Mallinckrodt. Diversifying suppliers reduces concentration risk, while policy-driven reshoring incentives introduced in 2023–24 could materially alter Mallinckrodt’s cost structure and capital allocation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariffs\/export controls: raise supply risk\u003c\/li\u003e\n\u003cli\u003eChina\/India: \u0026gt;60% of API supply\u003c\/li\u003e\n\u003cli\u003eDiversification: mitigates concentration\u003c\/li\u003e\n\u003cli\u003eReshoring incentives 2023–24: reshape costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health priorities and pandemic readiness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNational preparedness agendas directly drive demand for respiratory and critical care drugs, with emergency use frameworks enabling temporary market access during declared crises. Political attention shifts funding for neonatal programs, causing short-term order volatility but often prompting long-term investment in neonatal and critical-care infrastructure. Post-crisis reallocation can shrink immediate procurement yet expand future hospital capacity and recurring drug demand.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreparedness-driven demand\u003c\/li\u003e\n\u003cli\u003eEmergency use = temporary access\u003c\/li\u003e\n\u003cli\u003eNeonatal funding volatility\u003c\/li\u003e\n\u003cli\u003eShort-term cuts, long-term infrastructure growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare negotiation (2026) pressures specialty margins; orphan drugs \u0026gt;7,000; API risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare negotiation under the 2022 Inflation Reduction Act begins 2026, pressuring specialty margins; FDA\/EMA orphan pathways (over 7,000 orphan designations since 1983) speed access but raise post-market obligations. OECD shows ~73% public health financing (2022), while China\/India supply \u0026gt;60% of APIs; 2023–24 reshoring incentives may raise manufacturing costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiation\u003c\/td\u003e\n\u003ctd\u003eStarts 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan designations\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;7,000 (since 1983)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic health spend\u003c\/td\u003e\n\u003ctd\u003e~73% (OECD, 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI supply\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% China\/India\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental and Legal forces uniquely impact Mallinckrodt, with data-backed insights and forward-looking scenarios to identify risks and opportunities; formatted for executives, consultants and investors to insert directly into plans, pitches and strategy work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClean, summarized Mallinckrodt PESTLE analysis, visually segmented by category for quick interpretation, easily shareable and drop‑in ready for presentations to support discussions on external risk, regulatory pressures, and market positioning across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic cycles and hospital budgets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEconomic slowdowns compress hospital capital and formulary spending, pushing cost-containment and delaying elective purchases as IMF forecasts global growth of 3.2% in 2024, tightening margins. Specialty therapies face stepped utilization management in downturns even though specialty medicines accounted for about 50% of global drug spend in 2023 (IQVIA). Stable growth supports uptake of high-value rare-disease treatments, while annual hospital budget cycles and quarter timing drive tender wins and inventory build-ups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer mix and reimbursement dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShifts between public and private payers—public programs account for about 45% of US health spending—reshape Mallinckrodt net pricing and access. Specialty drugs drive ~55% of US drug spend, making co-pay tiers and specialty pharmacy networks critical for uptake. Outcome-based contracts can stabilize revenue but raise analytics and real-world evidence obligations. International reference pricing in many OECD markets transmits price cuts across countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation, FX, and input costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSterile manufacturing, biologics materials and energy are highly inflation-sensitive, with US CPI at 3.4% in 2024 and Brent crude averaging about 81 USD\/bbl, pressuring COGS for Mallinckrodt’s complex injectables. Currency swings (DXY rose roughly 5% in 2024) can compress reported international revenues versus locally incurred production costs. Long-dated supply contracts often lag cost pass-through, creating margin drag. Active hedging and dual-sourcing are used to protect gross margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital availability and cost of debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBiopharma R\u0026amp;D and manufacturing upgrades demand steady capital; with the US federal funds rate near 5.25–5.50% (mid‑2024 to 2025) and 10‑yr Treasuries around 4.2%, borrowing costs and hurdle rates for new Mallinckrodt programs have risen materially, tightening project economics. Covenant limits from post‑restructuring debt can constrain BD\/licensing agility, while strong cash conversion from in‑line brands supports targeted reinvestment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003erates: Fed 5.25–5.50%\u003c\/li\u003e\n\u003cli\u003e10y: ~4.2%\u003c\/li\u003e\n\u003cli\u003eimpact: higher hurdle rates, pricier capex\u003c\/li\u003e\n\u003cli\u003erisk: covenant constraints on deals\u003c\/li\u003e\n\u003cli\u003emitigant: strong cash conversion from in‑line brands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing demand cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContract manufacturing demand rises with broader pipelines and small-batch biologics, supported by an estimated CMO market CAGR around 6–7% in recent 2023–2028 reports; client funding cycles and inventory normalization in 2024–2025 caused quarter-to-quarter order volatility for many CMOs. Capacity utilization swings drive margin variability, and Mallinckrodt's ability to win multi-year CMO work hinges on maintaining a strong quality reputation to secure long-term contracts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket CAGR ~6–7% (2023–2028)\u003c\/li\u003e\n\u003cli\u003eSmall-batch biologics share rising (2024 demand driver)\u003c\/li\u003e\n\u003cli\u003eClient funding\/inventory cycles = order volatility\u003c\/li\u003e\n\u003cli\u003eCapacity utilization impacts margins\u003c\/li\u003e\n\u003cli\u003eQuality reputation crucial for long-term CMO wins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare negotiation (2026) pressures specialty margins; orphan drugs \u0026gt;7,000; API risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic slowdowns tighten hospital budgets and formularies as IMF sees 2024 global GDP ~3.2%, pressuring Mallinckrodt margins. Higher rates (Fed 5.25–5.50%, 10y ~4.2%) raise hurdle rates and capex costs; CPI ~3.4% and Brent ~$81\/bbl push COGS. Specialty medicines (~50% global drug spend 2023) and public payers (~45% US health spend) shape pricing, access, and contract risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal GDP 2024 (IMF)\u003c\/td\u003e\n\u003ctd\u003e~3.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10y Treasury\u003c\/td\u003e\n\u003ctd\u003e~4.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPI 2024 (US)\u003c\/td\u003e\n\u003ctd\u003e~3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrent\u003c\/td\u003e\n\u003ctd\u003e~$81\/bbl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty share (2023)\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic payer share (US)\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMallinckrodt PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. This Mallinckrodt PESTLE analysis examines political, economic, social, technological, legal and environmental factors affecting the company, with actionable insights for investors and strategists. No placeholders or teasers—this is the final, ready-to-download file you’ll get immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162732638585,"sku":"mallinckrodt-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/mallinckrodt-pestle-analysis.png?v=1762707924","url":"https:\/\/portersfiveforce.com\/products\/mallinckrodt-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}